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Background: There is overwhelming evidence that dietary supplementation with n-3 polyunsaturated fatty acids
(PUFAs), mainly EPA (C20:5n-3) and DHA (C22:6n-3), has cardiovascular protective effects on patients with type 2
diabetes mellitus (T2DM) but not on healthy people. Because the T2DM heart increases fatty acid oxidation (FAO)
to compensate for the diminished utilization of glucose, we hypothesize that T2DM hearts consume more n-3
PUFAs and, therefore, need more n-3 PUFAs. In the present study, we investigated the changes in cardiac n-3
PUFAs and peroxisomal beta-oxidation, which are responsible for the degradation of PUFAs in a high-fat diet (HFD)
and low-dose streptozotocin- (STZ) induced type 2 diabetic rat model.
Methods and results: The capillary gas chromatography results showed that all the n-3 (or omega-3) PUFAs,
especially DHA (~50%) and EPA (~100%), were significantly decreased, and the n-6/n-3 ratio (~115%) was
significantly increased in the hearts of diabetic rats. The activity of peroxisomal beta-oxidation, which is crucial to
very-long-chain and unsaturated FA metabolism (including DHA), was significantly elevated in DM hearts.
Additionally, the real-time PCR results showed that the mRNA expression of most peroxisomal beta-oxidation
key enzymes were up-regulated in T2DM rat hearts, which might contribute to the reduction of n-3 (or omega-3)
PUFAs.
Conclusion: In conclusion, our results indicate that T2DM hearts consume more n-3 PUFAs, especially DHA and
EPA, due to exaggerated peroxisomal beta-oxidation.
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Type 2 diabetes mellitus (T2DM) is associated with high
cardiovascular morbidity and mortality [1]. In patients
with diabetes, the fatty acid (FA) supply to the heart
increases to compensate for the diminished utilization of
glucose as an energy source. Although the dramatic in-
crease in FA influx markedly increases the fatty acid oxi-
dation (FAO) [2], it also leads to elevated FA and
subsequent triglyceride (TG) synthesis in the diabetic
heart, causing cellular lipotoxicity and the initiation of
cardiac dysfunction [3]. Alternatively, the diabetic heart* Correspondence: jianglingling1959@163.com
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reproduction in any medium, provided the oris characterized by significant alterations in the fatty acid
composition of heart membranes. It has been shown
that the linoleic acid (C18:2n-6) content is increased [4]
and the n-3 polyunsaturated fatty acid (PUFA) content is
decreased [5] in the cardiac phospholipids of STZ-
treated rats and fructose-fed rats.
Fatty acids are degraded by both mitochondrial and
peroxisomal β-oxidation. The fatty acids that are shorter
than C20 are primarily oxidized in the mitochondria,
and the fatty acids that are greater than C22 (very-long-
chain fatty acids, VLCFA), including polyunsaturated
fatty acids (PUFA, Polyenoic acids with 20–22 carbon
atoms and 3–6 double bonds), are primarily oxidized
in the peroxisomes [6]. The fatty acid oxidation of
cardiac fatty acids is controlled, in part, at the gene reg-
ulatory level [7,8]. The nuclear receptor peroxisome pro-
liferator-activated receptor α (PPARα), a ligand-activated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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scriptional control of genes involved in cardiac fatty acid
oxidation [2]. Long-chain fatty acids and a variety of
related compounds serve as PPARα ligands [9]. Some of
the genes encoding peroxisomal (acyl-CoA oxidase,
ACOX) and mitochondrial (muscle isoform of carnitine
palmitoyltransferase-1, mCPT-1) FAO enzymes have
been identified as PPARα targets [10]. Animal studies
have shown that in the diabetic heart, some of the
changes in mitochondrial function and mitochondrial
FAO occur via the PPARα gene regulatory pathway
[2,11]. While previous work on the fatty acid changes
and mitochondrial FAO of the heart has focused on the
STZ-induced diabetic rat, it is clear that the n-3 PUFAs,
especially eicosapentaenoic acid (EPA; C20:5n-3) and
docosahexaenoic acid (DHA; C22:6n-3), are important
for heart function. Furthermore, a higher intake of diet-
ary long chain n-3 PUFAs has an overall beneficial effect
on heart diseases [12,13]. Recent studies have high-
lighted the important role of long chain n-3 PUFAs
in vivo not only as a composition of biomembrane but
also as PPARα ligands that cause subsequent alterations
in hormonal signaling [14,15]. According to this hypoth-
esis, the level of EPA and DHA in the heart could pro-
vide information on the risk of heart diseases. In this
study, we used a high-fat diet plus a low-dose of STZ to
induce the type 2 diabetic SD rat, which is known to de-
velop many features reported in patients with uncon-
trolled type 2 diabetes mellitus [16,17], including
hyperglycemia, polyuria, and loss of body weight. We
examined the free long chain n-3 PUFA composition,
the peroxisomal FAO activity, and the mRNA expression
of genes encoding the peroxisomal FAO enzymes in the
diabetic heart to evaluate the role of DHA and peroxi-
somal FAO in type 2 diabetic hearts.Methods
Induction of experimental type 2 diabetes in rats
Type 2 diabetic rats were induced by the combination of
a high-fat diet (HFD) and a low-dose STZ as described
by Srinivasan [16]. Male Sprague-Dawleys (SD) rats
weighing 200–220 g were obtained from the Experi-
mental Animal Center of the Hebei Medical University,
Shijiazhuang, Hebei Province, China. After 1 week of
acclimation, the rats were randomly divided into a con-
trol group and a challenge group, and they were fed a
normal pellet diet (NPD) consisting of 10.3% fat, 24.2%
protein and 65.5% carbohydrate and a HFD consisting
of 59.8% fat (mainly pork), 20.1% protein and 20.1%
carbohydrate. After 8 weeks of dietary manipulation, an
oral glucose tolerance test (OGTT) was performed as
per the literature method to confirm the insulin resist-
ance (IR) of the challenge group rats [17].Diabetes was induced by a single intraperitoneal injec-
tion of streptozotocin (STZ; Alexis, USA; 25 mg/kg i.p.
in a 0.1 mol/L citrate buffer, pH 4.5) given to rats with
insulin resistance. The NPD rats (CON group) were
given via the i.p. route in a citrate buffer vehicle. One
week after STZ administration, rats with fasting blood
glucose (FBG) ≥11.1 mmol/L in two consecutive ana-
lyses were considered to be the type 2 diabetic rat model
(DM group). All animals remained on the assigned diet
until the terminal experiment.
After 8 weeks of diabetes, the FBG was performed
again: CON (5.0 ± 0.4 mmol/L) and DM (12.7 ±
1.9 mmol/L). Then, the rats were anaesthetized by using
20% urethane (1.2 g/kg intraperitoneally), and plasma
(8–10 ml per animal) was immediately collected from
the femoral artery and processed into serum. After being
washed in ice-cold saline solution, the hearts were
weighed and frozen in liquid nitrogen, then stored at
−80°C. All experimental procedures were performed in
accordance with the guidelines established by the Ethics
Review Committee for Animal Experimentation (Hebei
Medical University, Shijiazhuang, China).
Determination of total free fatty acids and triglycerides
with the kit
The total free fatty acids and triglycerides in the serum
and heart were measured with the commercial assay kits
(Jiancheng, China) following the manufacturer’s instructions.
Analysis of serum and cardiac free fatty acids by capillary
gas chromatography
The lipids were extracted from the serum and heart
according to a modification of the literature procedures
[18] in methanol-dichloromethane (3:1, vol/vol). The
supernatant was vortex-mixed with natrii sulfas exsicca-
tus (as a dehydrant). The dehydrated supernatant was
obtained by centrifugation, and it was transferred into a
screw-capped glass tube for further fatty acid methyla-
tion. Fatty acid methyl esters were prepared by proce-
dures similar to the literature method [19] using an
acetyl chloride/methanol reagent.
Then, the fatty acid methyl esters solved in normal
heptane were separated by capillary GLC (Agilent
7890A) using a 30 m × 0.53 mm × 1.00 μm polyethylene
glycol column (DB-WAX, Agilent). Split injection (10:1)
and flame-ionization detection (FID) were achieved at
300°C. The initial oven temperature programming
was 150°C isothermal for 1 min, increased to 190°C at
10°C/min, held isothermal for 58 min at this temperature,
then increased to 230°C at 20°C/min and held isothermal
for 15 min at 230°C with a Nitrogen gas flow rate of
80 cm/s as the carrier gas. Fatty acids were identified by
comparison with standard mixtures of fatty acid methyl
esters (Fatty Acid methyl esters are listed in Table 1;
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the respective standard curve and expressed as μg/g tissue
or μg/ml serum.
Analysis of cardiac fatty acid β-oxidation activity
Rat heart homogenates (10% w/v) were prepared in a
medium containing 0.25-M sucrose, 1-mM EDTANa3,
and 3-mM Tris–HCl buffer at a pH of 7.0. The homoge-
nates were centrifuged for 5 min at 1000 g. The resulting
supernatants were used for the following activity assays.
Assay of the total activity of fatty acid β-oxidation by
spectrophotometry
Both mitochondrial and peroxisomal β-oxidation path-
way contains the reaction of NAD+ to NADH+H+.
Therefore, the total activity of mitochondrial and peroxi-
somal β-oxidation was routinely assayed by the
palmitoyl-CoA-dependent NAD+ reduction method [20].
The assay mixture contained a 30 mM potassium
phosphate buffer at pH 8.2, 0.5-mM NAD, 0.2-mM
CoA, 1-mM dithiothreitol, 0.15 mg/ml of bovine serum
albumin, 0.01% Triton X-100, and, at most, 500 μg of
protein/ml of assay. The temperature was maintained
at 37°C. The reaction was initiated by the addition of
50-μM palmitoyl-CoA. NAD reduction was followed
spectrophotometrically at 340 nm.
Assay of peroxisomal β-oxidation activity by
luminometric assay
The heart homogenates were prepared exactly the same
as the total activity of fatty acid β-oxidation detection.
Only the peroxisomal β-oxidation pathway contains theTable 1 Changes of serum and cardiac FFA composition in CO
Fatty acid Serum (μm
CON
C16:0(palmitic acid) 324 ± 21
C18:0(octadecanoic acid) 202 ± 22
C20:0(arachidic acid) 3.9 ± 0.2
C22:0(behenic acid) 4.7 ± 0.4
C24:0(lignoceric acid) 9.1 ± 1.7
C16:1n-7(palmitoleic acid) 13.1 ± 1.8
C18:1n-9(oleic acid, OA) 83.4 ± 23.3
C18:2n-6(linoleic acid, LA) 255 ± 28
C20:4n-6(arachidonic acid, AA) 227 ± 15
C22:4n-6(docosatetraenoic acid) 1.4 ± 1.1
C18:3n-3(α-linolenic acid, LNA) 7.4 ± 0.7
C20:5n-3(eicosapentaenoic acid, EPA) 10.1 ± 1.1
C22:5n-3(docosapentaenoic acid, DPA) 3.6 ± 1.3
C22:6n-3(docosahexaenoic acid, DHA) 47.4 ± 2.1
n-6/n-3 7.1
Data represent the means ± SD. * P < 0.05 vs. CON; ** P < 0.01 vs. CON. ND: not dereaction of H2O2 production and H2O2 content can be
detected exactly by luminometric reaction. The lumino-
metric assay for peroxisomal β-oxidation detection was
performed according to Osmundsen [20]. Briefly, an
assay mixture was used that contained 0.1-M potassium
phosphate, 20-μM luminol, 4-mM NaN3, 10 μg of horse-
radish peroxidase/ml, 0.5 mg of defatted bovine serum
albumin/ml, 25-μM palmitoyl-CoA, 100-μM NAD and
5-mM EDTANa3, at pH 8.5.
The reaction was initiated by the addition of 10 μl of
heart homogenates. The temperature was maintained at
25°C. After 10 min, the mixture was immediately trans-
ferred to a sample chamber of multifunction chemilu-
minescence detector IFFS-A. Then, the luminol mixture
was injected, and the relative luminous intensity at its
peak height was recorded. Then, the H2O2 amount was
calculated by using a standard H2O2 curve. Finally, the
activity of peroxisomal β-oxidation (mU/mg) was calcu-
lated by using the following formula: 1000 × H2O2 (μM)/
[reaction time (min) × protein concentration (mg/L)].
Assay of mRNA by quantitative real-time PCR
The total RNA was extracted from the heart using the
PROMEGA SV Total RNAs Isolation System (PRO-
MEGA Inc., CA, USA). Both the synthesis of comple-
mentary DNA (cDNA) from 2000 ng of total RNA and
the subsequent PCR amplification was carried out by the
SYBR PrimeScript RT PCR kit (Takara, Tokyo). The
amplification and detection were performed with a Rotor
Gene real-time detection system 6.1 (QIAGEN, Valencia,
CA, USA). Gene-specific primers used in the present
study (Table 2) were designed using the sequencesN and DM groups (n = 12)
ol/ml) Heart (μmol/g prot)
DM CON DM
453 ± 56 ** 1481 ± 108 1593 ± 118
334 ± 31 ** 2193 ± 197 2835 ± 129**
5.1 ± 0.2 * 13.0 ± 1.1 14.4 ± 1.3
7.5 ± 0.9 ** 21.9 ± 1.5 21.7 ± 2.9
8.8 ± 0.7 36.4 ± 4.7 26.0 ± 1.6**
12.2 ± 3.0 42.6 ± 10.8 41.5 ± 4.3
259 ± 69 ** 859 ± 113 1994 ± 209**
231 ± 20 1473 ± 99 1724 ± 229**
250 ± 19 1330 ± 130 1318 ± 145
10.0 ± 1.3** 49.5 ± 8.1 127 ± 11**
2.8 ± 0.4 ** 20.5 ± 6.5 11.3 ± 2.2**
8.2 ± 0.5 ** 10.0 ± 1.4 ND
3.5 ± 1.3 81.7 ± 7.5 47.2 ± 6.9**
50.6 ± 3.8 613 ± 62 317 ± 61**
7.9 3.9 8.4
tected.
Table 2 Primers for real-time PCR analysis
Gene Forward primer Reverse primer Product (bp)
18S CGCCGCTAGAGGTGAAATTC CCAGTCGGCATCGTTTATGG 149
PPARα TGGAGTCCACGCATGTGAAG TGTTCCGGTTCTTTTTCTGAATCT 113
m-CPT1 AAACATCACTGCCCAAGC ACTCCATGCGGAAATAGG 108
ACOX1 GTTGATCACGCACATCTTGGA TCGTTCAGAATCAAGTTCTCAATTTC 78
ACOX3 TGGAGAAGGAACGAGAACTGAAC ACATGTGGAGGACACATTTGTTG 165
LBP TTTTAAAATGGGACCCTTCAGAGT CCCCTTGCGAATTTTCCAA 70
DBP GGTGGTAAAGAAAGTAAATG AATTGTGATGGTCGTGTC 148
THLA GGTATGAGATCAATGCTGCC GGTGCATTTGGACATTTGTAG 131
THLB GGCACAAGGGCATCCAATC GTGCGCTGTCTTTGGTTCAA 51
SCPx TATGGAATGTCTGCCTGTCC CCAGTGCTTCATAAGTCAGG 510
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ware Primer Premier 5.0. To demonstrate the specificity
of the PCR product, a melting curve analysis was per-
formed after PCR, and each curve was confirmed to be a
single peak (data not shown). The thermal cycling pro-
gram was as follows: 30 s denaturation step at 95°C fol-
lowed by 50 cycles of 5 s denaturation at 95°C, 20 s
annealing at 60°C, and 20 s extension at 72°C.
Statistical analysis
Results were expressed as the mean ± SD. The difference
was analyzed by Student’s t test. Correlation was deter-
mined with the spearman correlation test (SPSS 13.0). P
< 0.05 was considered statistically significant. Data were
expressed as the mean ± SD. In the case of quantitative
real-time PCR data, Ct values of the test genes were nor-
malized by the average Ct values of 18S rRNA for each
pooled sample. Fold changes were obtained using 2
(−ΔΔCt), and standard deviations of fold changes were
determined according to the literature procedures [21].
Results
Total free fatty acids and triglycerides in serum and heart
At the end of the experiment, serum and cardiac total
free fatty acids (FFA) and triglycerides (TG) were mea-
sured in the rats of the two groups. As shown in Table 3,
serum FFA levels were 1.69-fold higher (1.56 ±
0.08 μmol/ml, p < 0.01) in the DM rats than in the CON
rats (0.58 ± 0.11 μmol/ml), and serum TG levels wereTable 3 At the end of the experiment, serum and heart
total FFA and total TG in CON and DM groups (n = 12)
Serum (μmol/ml) Heart (μmol/g prot)
CON DM CON DM
total FFA 0.58 ± 0.11 1.56 ± 0.08* 0.29 ± 0.05 0.49 ± 0.11*
total TG 3.75 ± 1.68 18.18 ± 4.12* 0.75 ± 0.14 1.84 ± 0.42*
Data represent the means ± SD. * P < 0.01 vs. CON. FFA: free fatty acid; TG:
triacylglycerol.nearly 4-fold higher (18.18 ± 4.12 μmol/ml, p < 0.01) in
the DM rats than in the CON rats (3.75 ± 1.68 μmol/
ml). In comparison with CON (0.29 ± 0.05 and 0.75 ±
0.14 μmol/g prot for FFA levels and TG levels, respect-
ively), the DM rats increased cardiac FFA levels by 0.69-
fold (0.49 ± 0.11 μmol/g prot, P < 0.01) and TG levels by
1.45-fold (1.84 ± 0.42 μmol/g prot, P < 0.01).Fatty acid profile in serum and heart
To further investigate the changes of different fatty acids
in diabetic serum and hearts, we observed 14 different
types of FFA by capillary gas chromatography assay
(Table 1).
In serum, 6 of 14 FAs including SFAs, including C16:0
(~40%), C18:0 (~65%), C20:0 (~31%) and C22:0 (~60%),
MUFAs, including C18:1n-9 (~211%), and PUFAs, in-
cluding C22:4n-6 (~614%), were significantly increased
in the DM group compared with the control group. Only
the LNA (C18:3n-3) and EPA (C20:5n-3) were 62% and
19% lower, respectively, in DM serum than in CON
serum. Additionally, there was no significant change in
n-6/n-3 ratio between the two groups.
In the heart, 4 of 14 FAs, including SFAs, including
C18:0 (~29%), MUFAs, including C18:1n-9 (~132%), and
PUFAs, including C18:2n-6 (~17%) and C22:4n-6
(~157%), were significantly increased in the DM group
compared with the control group. Although the total
FFA of the DM heart was significantly increased, 5 of 14
FAs were significantly decreased. C24:0 was 29% lower
in the DM heart than in the CON heart. Most import-
antly, we found that all the n-3 series PUFAs, including
LNA (~45%), EPA (~100%), DPA (~42%) and DHA
(~48%), were dramatically decreased in the DM hearts
compared to the CON hearts. Moreover, accompanied
with a slight increase in the sum of n-6 PUFAs (~11%),
the dramatic decrease in sum of n-3 PUFAs made the
n–6/n-3 ratio ~115% higher in the DM hearts than in
the CON hearts.
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β-oxidation in the heart
Fatty acids are degraded by β-oxidation. We first ana-
lyzed the total β-oxidation (including mitochondrial and
peroxisomal β-oxidation) activities in the heart. As
shown in Figure 1A, the total fatty acid β-oxidation ac-
tivities of DM hearts (3.02 ± 0.61 mU/mg prot, P < 0.01)
increased by 76% compared with CON hearts (1.71 ±
0.33 mU/mg prot). We further determined the cardiac
peroxisomal β-oxidation activity by a luminometric
assay. As shown in Figure 1B, the peroxisomal β-
oxidation activity in the DM hearts was increased by
~30% (39.2 ± 5.5 mU/mg prot, P < 0.01) compared to the
CON hearts (30.1 ± 3.6 mU/mg prot).
After determining the cardiac fatty acid profile result,
we analyzed the relationship of EPA, DPA and DHA
content with the peroxisomal β-oxidation activity in
heart. A correlation analysis showed that there
were negative correlations between the abundance of
EPA (r = −0.67, P < 0.001), DPA (r = −0.63, P < 0.001) and
DHA (r = −0.83, P < 0.001) and the activity of peroxi-
somal β-oxidation in rat hearts (Figure 2). Thus, the
decreased EPA, DPA and DHA in the DM hearts were
thought to be largely attributable to elevated peroxi-
somal β-oxidation activity.
mRNA levels of mitochondrial and peroxisomal enzymes
In this study, we obtained the mRNA expression of per-
oxisome proliferator-activated receptor α (PPARα),
muscle carnitine palmitoyltransferase 1 (mCPT-1) and
peroxisomal β-oxidation enzyme genes, including acyl-
CoA oxidase 1 (ACOX1), acyl-CoA oxidase 3 (ACOX3),
D-bifunctional protein (DBP), L-bifunctional protein
(LBP), 3-Ketoacyl-CoA thiolase A/B (THLA/B) and
sterol carrier protein x (SCPx), in the heart using real-
time RT-PCR (corrected by 18S rRNA).
PPARα is a critical transcriptional regulator of cardiac




































Figure 1 Comparison of the total activity of fatty acids β-oxidation (A
rat hearts (n = 12). Values are means ± S.E.M. ** P < 0.01 vs. CON.mRNA expression of cardiac PPARα was not changed
between the DM and CON group. The mCPT-1 is a key
enzyme in mitochondrial β-oxidation in the heart, and
the relative expressions of mCPT-1 mRNA in the DM
group was higher (P < 0.01) than in the CON group. It
indicated that the FA utilization of mitochondria was
elevated in the diabetic heart. In peroxisomal pathways
of β-oxidation, enzymes of catalytic dehydrogenation are
ACOX1 and ACOX3; enzymes of catalytic imbitition
and redehydrogenation are LBP and DBP; enzymes of
catalytic thioclastic reaction are THLA/B and SCPx [10].
And the expression at the mRNA levels of almost all of
the peroxisomal β-oxidation enzymes, except LBP, were
significantly enhanced (P < 0.01) in the DM group com-
pared to the CON group. Therefore, the increased per-
oxisomal β-oxidation activity was caused at least in part
by the enhanced mRNA levels of peroxisomal β-
oxidation enzymes in the DM heart.
Discussion
In the heart, FAs contribute approximately 70% of the
ATP necessary for normal heart function. During dia-
betes, there is an increased FA supply to the diabetic
heart to compensate for the diminished contribution of
glucose as an energy source due to insulin deficiency
[22]. Because of the dramatic increase in FA influx com-
pared to FA oxidation, FA and TG accumulation occurs
in the heart [3,23], leading to lipotoxicity [24]. Consist-
ent with these reports, we found that although the activ-
ity of total and peroxisomal fatty acid β-oxidation was
increased, the accumulation of TG and total free fatty
acid in the diabetic heart occurred in tandem with
increases in serum TG and total free fatty acid.
Mitochondrial β-oxidation constitutes the major
process by which most of the short- (<C8 ), medium-
(<C14 ), and long-chain (<C22 ) saturated and unsatur-
ated fatty acids are oxidized to generate energy. In the
















































































Cardiac peroxisomal β -oxidation activity
Figure 2 Significant correlation of peroxisomal β-oxidation activity and EPA (A), DPA (B) and DHA (C) levels in rat hearts
(□, CON; ▲, DM).
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fold, 0.31-fold, and 0.59-fold, respectively) and a
significant increase in the fatty acids of C18:1n-9 and
C22:4n-6 (2-fold and 6-fold, respectively). We also found
decreases in the fatty acids of C18:2n-6 and C18:3n-3
(0.13-fold and 0.62-fold, respectively) in the serum with
an increase in the fatty acids of C18:0, C18:1n-9, and
C22:4n-6, (0.29-fold, 1.3-fold, and 1.5-fold, respectively)
and a decrease in the fatty acids of C18:3n-3 (0.45-fold)
in the heart. Considered together with the increase in
total fatty acid oxidation activity and mRNA levels of theFigure 3 Change in mRNA expression of PPARα, mCPT-1 and peroxiso
Values are means ± S.E.M. * P < 0.01 vs. CON.mCPT-1 gene, which encodes the rate-limiting enzyme
in mitochondrial β-oxidation, it suggests that the type 2
diabetic heart removed more fatty acids from circulation
to provide energy though mitochondrial β-oxidation; this
supports the common view that in diabetes, the FA sup-
ply is in excesses, causing the increased cellular oxidative
capacity, intracellular TG and FFA accumulation, which
is associated with lipotoxicity [25].
It was reported that in STZ-induced insulin deficiency,
because of the decrease in 6-desaturase activity, the key
enzyme in the conversion of linoleic acid to long-chainmal enzymes in CON and DM rat hearts (n = 12 in each group).
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observed in both cardiac and mitochondrial phospholi-
pids [5]. Because the serum C18:2n-6 was decreased and
the cardiac mitochondrial β-oxidation was increased in
our results, the increase of cardiac C18:2n-6 may also be
due to the decrease of 6-desaturase activity.
Peroxisomes are the major sites of degradation of very
long-chain saturated fatty acids and polyunsaturated
fatty acids by the sequential action of ACOX1 or
ACOX3, DBP or LBP, and THLA/B or SCPx. In the
present type 2 diabetic hearts, in addition to mitochon-
drial oxidation, peroxisomal β-oxidation was also
observed to be enhanced; this was indicated by increases
in activity and mRNA levels of genes involved in the
peroxisomal pathway, together with the decrease in lig-
noceric acid (C24:0) levels that were β-oxidized only by
the peroxisomal pathway [26]. Regarding PUFA, peroxi-
somal β-oxidation takes a dual function: synthesis and
degradation [27,28]. Although peroxisomal β-oxidation
participates in the synthesis of DHA in some organs,
such as the liver and brain, it has been reported that the
rat heart cannot synthesize DHA from circulating ALA
because it lacks elongase-2 [29]. Thus, the content of
PUFA in the heart depends on the transportation to the
heart from circulation and degradation in the heart. In
our study, the content of EPA, DPA and DHA were sig-
nificantly decreased in the DM heart, but changes were
slight in diabetic serum compared with CON serum.
Moreover, the activity of peroxisomal β-oxidation in the
diabetic heart correlated negatively with the content of
EPA, DPA and DHA. Therefore, the decrease in cardiac
long chain PUFAs, including EPA, DPA and DHA, might
be related to the elevated peroxisomal β-oxidation activ-
ity observed in this study.
It is worth noting that all the observed n-3 PUFAs
were significantly decreased in the type 2 diabetic
hearts. Moreover, because of the significant decrease in
n-3 PUFAs and the slight increase in n-6 PUFAs, the
n-6/n-3 ratio was doubled in the diabetic heart. During
the past 3 decades, thousands of epidemiologic, observa-
tional, experimental, and randomized controlled studies
have been published regarding the cardiovascular pro-
tective effects of n-3 PUFAs, especially DHA and EPA.
For example, DHA and EPA can ultimately increase
arrhythmic thresholds, increase the threshold of ven-
tricular fibrillation, increase heart rate variability, reduce
ischemic damage, and favorably affect autonomic tone
[30-32]. Furthermore, several authors tended to explain
the PUFAs effects in terms of a balance between n-6 and
n-3 FAs, rather than the absolute amount of each single
molecule. In the most simplistic interpretation, a very
high n-6/n-3 ratio is considered detrimental for human
health [30]. These data, therefore, showed that the reduc-
tion of the n-3 PUFA content (mainly EPA, DPA andDHA) and a high n-6/n-3 ratio might be another factor
associated with type 2 diabetic hearts in addition to the
accumulation of the ectopic free fatty acids and TG. This
may also explain why a higher intake of dietary long
chain n-3 PUFA, especially EPA and DHA, is required
for heart diseases in type 2 diabetes [12].
In some studies, the activation of PPARα and subse-
quent enhanced expression of the PPARα target gene,
which increases fatty acid oxidation, were observed dur-
ing insulin resistance and diabetes [33,34]. In our results,
although the mRNA expression of PPARα had no
changes, the enhanced mRNA expressions of ACOX1, 3
and mCPT-1 (PPARα targets) represented the activation
of PPARα in the type 2 diabetic rat heart.
In conclusion, we found that, except for the increasing
mitochondrial β-oxidation, the activity of peroxisomal β-
oxidation was also significantly increased in type 2 dia-
betic rat hearts. The increasing activity was, at least
partly, due to the elevated expression of genes involved
in peroxisomal β-oxidation, especially ACOX1 and 3
(PPARα targets). The enhanced peroxisomal β-oxidation
and reduced n-3 PUFA content might be another ad-
verse factor associated with type 2 diabetic hearts.
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